| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Cancer Research Campaign Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham NG5 1PB, United Kingdom
The 791Tgp72 antigen has been used successfully as a target for tumor imaging and T-cell immunotherapy. We have characterized this antigen using the monoclonal antibody 791T/36 as a 72/66 kDa doublet. NH2-terminal protein sequencing of the two bands revealed identity with the complement regulatory protein CD55. Antibodies recognizing different domains of CD55 were also shown to bind to the purified 791Tgp72, although sequence analysis of the cDNA cloned from 791T tumor cells showed 100% homology with CD55 and transfection of the cDNA into antigen-negative CHO cells resulted in binding of 791T/36. This identifies the tumor antigen 791Tgp72 as CD55. This protein protects cells from complement attack; however, it can also transduce signals in lymphocytes and is a ligand for CD97, expressed by activated T cells. These results suggest that CD55 plays a roll in signaling between the innate and adaptive immune responses. It is therefore a very intriguing target, because absence of the molecule makes the tumor cells susceptible to complement, whereas protective overexpression results in the antigen being a target for T-cell immunotherapy.
This article has been cited by other articles:
|
|
 |
|
  G. J. Ullenhag, I. Spendlove, N. F.S. Watson, A. A. Indar, M. Dube, R. A. Robins, C. Maxwell-Armstrong, J. H. Scholefield, and L. G. Durrant A Neoadjuvant/Adjuvant Randomized Trial of Colorectal Cancer Patients Vaccinated with an Anti-Idiotypic Antibody, 105AD7, Mimicking CD55 Clin. Cancer Res., December 15, 2006; 12(24): 7389 - 7396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liu, T. Miwa, B. Hilliard, Y. Chen, J. D. Lambris, A. D. Wells, and W.-C. Song The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo J. Exp. Med., February 22, 2005; 201(4): 567 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mustafa, A. Eckert, T. Klonisch, A. Kehlen, P. Maurer, M. Klintschar, M. Erhuma, R. Zschoyan, O. Gimm, H. Dralle, et al. Expression of the Epidermal Growth Factor Seven-Transmembrane Member CD97 Correlates with Grading and Staging in Human Oral Squamous Cell Carcinomas Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 108 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steinert, M. Wobus, C. Boltze, A. Schutz, M. Wahlbuhl, J. Hamann, and G. Aust Expression and Regulation of CD97 in Colorectal Carcinoma Cell Lines and Tumor Tissues Am. J. Pathol., November 1, 2002; 161(5): 1657 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Caragine, N. Okada, A. B. Frey, and S. Tomlinson A Tumor-expressed Inhibitor of the Early but not Late Complement Lytic Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer Cancer Res., February 1, 2002; 62(4): 1110 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Modak, K. Kramer, S. H. Gultekin, H. F. Guo, and N.-K. V. Cheung Monoclonal Antibody 8H9 Targets a Novel Cell Surface Antigen Expressed by a Wide Spectrum of Human Solid Tumors Cancer Res., May 1, 2001; 61(10): 4048 - 4054. [Abstract] [Full Text]
|
|
|
|
|
|
S. Chen, T. Caragine, N.-K. V. Cheung, and S. Tomlinson CD59 Expressed on a Tumor Cell Surface Modulates Decay-accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma Cancer Res., June 1, 2000; 60(11): 3013 - 3018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Amin, R. A. Robins, C. A. Maxwell-Armstrong, J. H. Scholefield, and L. G. Durrant Vaccine-induced Apoptosis: A Novel Clinical Trial End Point? Cancer Res., June 1, 2000; 60(12): 3132 - 3136. [Abstract] [Full Text]
|
|
|
|
|
|
L. G. Durrant, C. Maxwell-Armstrong, D. Buckley, S. Amin, R. A. Robins, J. Carmichael, and J. H. Scholefield A Neoadjuvant Clinical Trial in Colorectal Cancer Patients of the Human Anti-Idiotypic Antibody 105AD7, Which Mimics CD55 Clin. Cancer Res., February 1, 2000; 6(2): 422 - 430. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. S. Fedarko, B. Fohr, P. G. Robey, M. F. Young, and L. W. Fisher Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack J. Biol. Chem., May 26, 2000; 275(22): 16666 - 16672. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
